Headlines about Calithera Biosciences (NASDAQ:CALA) have been trending positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Calithera Biosciences earned a media sentiment score of 0.29 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.6085390701162 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the media stories that may have effected Accern’s analysis:
- BidaskClub Downgrades Calithera Biosciences, Inc. (NASDAQ:CALA) to Strong Sell (americanbankingnews.com)
- Sell-Side Research on Modine Manufacturing Company (MOD), Calithera Biosciences, Inc. (CALA) – StockNewsMagazine (stocknewsmagazine.com)
- Should You Buy Paratek Pharmaceuticals, Inc. (PRTK) or Calithera Biosciences, Inc. (CALA)? – StockNewsGazette (stocknewsgazette.com)
- Q3 2017 EPS Estimates for Calithera Biosciences, Inc. (NASDAQ:CALA) Cut by Leerink Swann (americanbankingnews.com)
- Calithera Biosciences, Inc. (NASDAQ:CALA) Technical Analysis Indicators – StockNewsGazette (stocknewsgazette.com)
Shares of Calithera Biosciences (NASDAQ CALA) traded up 15.35% on Friday, hitting $13.90. 1,034,907 shares of the stock traded hands. The stock’s 50 day moving average price is $15.88 and its 200 day moving average price is $12.74. The stock’s market cap is $493.12 million. Calithera Biosciences has a 52-week low of $2.20 and a 52-week high of $20.05.
Calithera Biosciences (NASDAQ:CALA) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.14. The business had revenue of $7.26 million during the quarter, compared to analyst estimates of $4.80 million. On average, equities analysts expect that Calithera Biosciences will post ($0.83) EPS for the current fiscal year.
A number of equities analysts have issued reports on CALA shares. Zacks Investment Research upgraded shares of Calithera Biosciences from a “hold” rating to a “strong-buy” rating and set a $21.00 price objective on the stock in a research report on Tuesday, July 11th. Wells Fargo & Company restated an “outperform” rating and issued a $20.00 price objective (up previously from $15.00) on shares of Calithera Biosciences in a research report on Tuesday, June 6th. BidaskClub upgraded shares of Calithera Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, July 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $19.00 target price (up previously from $14.00) on shares of Calithera Biosciences in a research note on Monday, June 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. Calithera Biosciences currently has a consensus rating of “Hold” and a consensus target price of $15.50.
TRADEMARK VIOLATION WARNING: “Positive Media Coverage Somewhat Unlikely to Affect Calithera Biosciences (NASDAQ:CALA) Share Price” was originally posted by BNB Daily and is owned by of BNB Daily. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.baseball-news-blog.com/2017/08/14/favorable-press-coverage-somewhat-unlikely-to-affect-calithera-biosciences-nasdaqcala-stock-price-updated-updated-updated.html.
In other news, VP Keith Orford sold 2,120 shares of Calithera Biosciences stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $18.31, for a total value of $38,817.20. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders sold a total of 3,470 shares of company stock worth $61,817 over the last ninety days. Corporate insiders own 16.30% of the company’s stock.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.